Featured Posts

Tuesday, February 5, 2019

Mallinckrodt Provides Update on Phase 4 Data H.P. Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Patients with Rheumatoid Arthritis (RA)

STAINES-UPON-THAMES, United Kingdom, Feb. 5, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, has completed the open-label phase of the ongoing Phase 4, multicenter study assessing the efficacy and safety of H.P. Acthar® Gel in patients ...



from PR Newswire: https://prn.to/2SyMiay

No comments:

Post a Comment